Stoke Therapeutics Inc [STOK] stock is trading at $5.90, down -1.83%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The STOK shares have lost -5.30% over the last week, with a monthly amount drifted -25.79%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Stoke Therapeutics Inc [NASDAQ: STOK] stock has seen the most recent analyst activity on December 20, 2024, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $24. On March 26, 2024, upgrade upgraded it’s rating to Outperform. TD Cowen downgraded its rating to a Market Perform. BofA Securities upgraded its rating to Neutral for this stock on May 01, 2023, and upped its price target to $12.
Stoke Therapeutics Inc [STOK] stock has fluctuated between $5.45 and $17.58 over the past year. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Stoke Therapeutics Inc [NASDAQ: STOK] shares were valued at $5.90 at the most recent close of the market. An investor can expect a potential return of 205.08% based on the average STOK price forecast.
Analyzing the STOK fundamentals
Stoke Therapeutics Inc [NASDAQ:STOK] reported sales of 36.55M for the trailing twelve months, which represents a growth of 707.07%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -2.77%, Pretax Profit Margin comes in at -2.43%, and Net Profit Margin reading is -2.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.42 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.63 points at the first support level, and at 5.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.26, and for the 2nd resistance point, it is at 6.61.
Ratios To Look Out For
For context, Stoke Therapeutics Inc’s Current Ratio is 5.81. Also, the Quick Ratio is 5.81, while the Cash Ratio stands at 3.2. Considering the valuation of this stock, the price to sales ratio is 8.73, the price to book ratio is 1.39.
Transactions by insiders
Recent insider trading involved Kaye Edward M. MD, Director, that happened on Mar 18 ’25 when 10382.0 shares were sold. Director, Kaye Edward M. MD completed a deal on Mar 19 ’25 to sell 8907.0 shares. Meanwhile, CHIEF MEDICAL OFFICER Ticho Barry sold 3884.0 shares on Mar 18 ’25.
